enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Allergan, Inc. - Wikipedia

    en.wikipedia.org/wiki/Allergan,_Inc.

    Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. [ 2 ]

  3. Allergan - Wikipedia

    en.wikipedia.org/wiki/Allergan

    Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.

  4. Actavis - Wikipedia

    en.wikipedia.org/wiki/Actavis

    Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial ...

  5. MAP Gets Inhaled by Allergan - AOL

    www.aol.com/2013/01/23/map-gets-inhaled-by-allergan

    For premium support please call: 800-290-4726 more ways to reach us

  6. MAP Gets Inhaled by Allergan - AOL

    www.aol.com/news/2013-01-23-map-gets-inhaled-by...

    Allergan announced Tuesday the acquisition of MAP Pharmaceuticals for about $958 million in cash. The companies previously agreed to co-promote MAP's inhalable migraine treatment Levadex if it ...

  7. Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc. - AOL

    www.aol.com/news/2013-01-22-allergan-inc-to...

    For premium support please call: 800-290-4726 more ways to reach us

  8. David E. I. Pyott - Wikipedia

    en.wikipedia.org/wiki/David_E._I._Pyott

    He believed selling to Valeant would not create long-term value for Allergan's shareholders due to Valeant's historic reliance on cost-cutting. [28] Pyott is known to value aggressive research and development for Allergan, which he said had enabled Allergan to launch several new products and increase annual sales by an average of 11% since 2011 ...

  9. Allergan Commences Cash Tender Offer for All Outstanding ...

    www.aol.com/news/2013-01-31-allergan-commences...

    For premium support please call: 800-290-4726 more ways to reach us